Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effect After Transplantation of CB-AC-02 in Patients With Alzheimer's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs CB-AC 02 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors CHA Bio & Diostech
- 06 Feb 2024 Planned End Date changed from 1 Dec 2021 to 1 Dec 2024.
- 06 Feb 2024 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2024.
- 06 Feb 2024 Status changed from recruiting to active, no longer recruiting.